

Document Detail

Type: PMF IBTS SPEC

Document No.: IBTS/PMF/SPEC/0207[4]

Title: WHOLE BLOOD, RECONSTITUTED, SUITABLE FOR

NEONATAL USE

Owner: QA DOC CON QA DOC CONTROL

Status CURRENT **Effective Date:** 19-May-2025 **Expiration Date:** 19-May-2027

Review

Review: IBTS PMF REVIEW

Level	Owner Role	Actor	Sign-off By
1	DOCUMENT CONTROLLER	BECKY WHITE	BECKY WHITE
2	SSCD WRITER IBTS	LIAM MORGAN	LIAM MORGAN
3	COMPONENTS HEAD OF DEPT MRTC	AINE FITZPATRICK	AINE FITZPATRICK
3	LABS PHS DIR IBTS	BARRY DOYLE	BARRY DOYLE
3	MEDICAL & SCIENTIFIC DIRECTOR	ANDREW GODFREY	ANDREW GODFREY
3	SSCD HEAD OF DEPT IBTS	AILEEN FARRELLY	AILEEN FARRELLY
4	QUALITY ASSURANCE REVIEWER IBTS	COLIN JOHNS	COLIN JOHNS

Change Orders

Changes as described on Change Order: <u>Change Order No.</u>

Change Orders - Incorporated

Changes as described on Change Order: Change Order No.

IBTS/CO/0219/25

PRODUCT MASTER FILE

TITLE: WHOLE BLOOD, RECONSTITUTED, SUITABLE FOR NEONATAL

USE

Change Description:

Revise the Labelling and Barcode Illustrations.

Reason for Change:

To update the PMFs with new Label Versions (Ref CC 208/23 & 002/24)

Change order No.:

IBTS/CO/0219/25

Referenced Documents

N/A

SmartSolve Roles

N/A

Training Type

N/A

SmartSolve Document Category

Category	Mobile	Cryobiology	Website	GDP
Yes / No	No	No	Yes	No

IRISH BLOOD TRANSFUSION SERVICE

PRODUCT MASTER FILE

Title: Whole Blood, Reconstituted, Suitable for Neonatal Use

Name of Products: WHOLE BLOOD, Reconstituted, Suitable for Neonatal Use. HCT:....

WHOLE BLOOD, Reconstituted, Suitable for Neonatal Use, Irradiated.

HCT:....

E Progesa Codabar Component Codes: 54270 / 54271

E Progesa ISBT – 128 Component Codes: E8211V00 / E8213V00

General Description: This component is prepared by combining a unit of red cells (following

removal of additive solution) with a unit of thawed fresh frozen plasma (group AB). The donors of the selected components meet the additional

criteria as being suitable for neonatal use..

General Specification: 2

General Specification.					
Parameter	Quality Requirement	Frequency of Control			
Volume	>340 mL	100%			
Haematocrit	≥0.35 L/L	100%			
Haemoglobin	≥ 40 g/unit	100%			
Leucocyte Content	< 1 x 10 ⁶ / unit	Counted in units of red cells (04333/E7429V00)			
Haemolysis at end of shelf life	< 0.8% of red cell mass	100%			
ABO Agglutinins	No High Titre Anti-A or Anti-B	100%			
CMV	CMV ab negative	100%			

Labelling: See Appendix I

Storage: Whole Blood, Reconstituted, Suitable for Neonatal Use. HCT:... / Whole

Blood, Reconstituted, Suitable for Neonatal Use, Irradiated, HCT:...should be

stored at $4^{\circ}C \pm 2^{\circ C}$.

IBTS/PMF/SPEC/0207	Ver. 4	Page 4 of 7
--------------------	--------	-------------

Irradiation:

Whole Blood, Reconstituted, Suitable for Neonatal Use HCT:...should be irradiated before transfusion provided this does not unduly delay the transfusion. Post irradiation the component code changes to 54271/E8213V00 and the product should be used within 6 hours. It **must** be irradiated prior to transfusion where the neonate has had a previous intrauterine transfusion.

Transportation:

The air temperature of transport containers for units of Whole Blood, Reconstituted, Suitable for Neonatal Use HCT:... / Whole Blood, Reconstituted, Suitable for Neonatal Use, Irradiated, HCT:... should be maintained between 2°C and 10°C during transport from the Irish Blood Transfusion Service to the place where they are intended for use. Transport time under these conditions normally should not exceed 8 hours.

Indications for Use: Whole Blood, Reconstituted, Suitable for Neonatal Use HCT:... / Whole Blood, Reconstituted, Suitable for Neonatal Use, HCT:... Irradiated, is suitable for exchange transfusion and is used to augment the oxygen delivery capacity of the blood where this is critically impaired.

Precautions in Use:

- Compatibility of red cells with the intended recipient must be verified by suitable pretransfusion testing.
- Red Cells, Washed / Red Cells, Washed, Irradiated should be infused intravenously through a set containing an inline 170-200 µm filter.
- No other solutions should be added to the bag or giving set.
- Components should be inspected visually for defects, leakage, abnormal colour or visible clots.

Adverse Effects Include:

- Circulatory Overload.
- Haemolytic transfusion reaction;
- Non-haemolytic transfusion reaction (mainly chills, fever and urticaria).

The risk is reduced by leucodepletion and washing

Pathogen transmission

- Despite careful donor selection and laboratory screening procedures, infections including Syphilis, Viral Hepatitis, HIV, HTLV 1 & 11 and other viruses and protozoa (e.g. malaria) may, in rare instances, occur.
- vCJD transmission
- Transmission of other pathogens that are not tested for or recognised.
- The risk of CMV transmission is minimal as the components are leucodepleted
- Sepsis due to bacterial contamination (reduced but not eliminated by bacterial screening)

Metabolic upset

- Possible elevated potassium level in massive transfusions, especially where patient is hypothermic or acidotic or has impaired renal function.
- Citrate toxicity, especially in neonates and in patients with impaired hepatic function.
- Hypocalcaemia.
- Hypoglycaemia.
- Hypokalaemia.

• Immunological effects

- Alloimunisation to HLA and red cell antigens.
- Graft vs Host Disease (GvHD) in immuno compromised recipients . The risk of GvHD is eliminated by irradiation
- Transfusion related Acute Lung injury (TRALI) by donor HLA/granulocyte antibodies.
- Post transfusion purpura (PTP).

Iron overload

In patients on chronic red cell transfusion support programmes.

Serious Adverse Reaction

Please inform the IBTS immediately about any event relating to suspected bacterial sepsis/ transfusion associated bacterial sepsis

Serious adverse reactions should be reported to:

National Haemovigilance Office Irish Blood Transfusion Service National Blood Centre James's Street Dublin 8

AND

Quality Assurance ManagerIrish Blood Transfusion Service

AT EITHER

National Blood Centre James's Street Dublin 8

OR

Munster Regional Transfusion Centre St Finbarr's Hospital Douglas Road, Cork

Shelf life

6 hours

APPENDIX I

E Progesa Codabar Component Code: 54270

E Progesa ISBT – 128 Component Code: E8211V00

Product Name

WHOLE BLOOD, Reconstituted, Suitable for Neonatal Use

HCT:....

Labelling and Barcode:

(for illustration purposes only - barcodes not suitable for scanning - label not to scale)



IBTS ver 4.0

WHOLE BLOOD, Reconstituted, Suitable for Neonatal Use.

HCT:

Store at 4°C ± 2°C





Drawn 09 May 2025



E8211V00

This component must not be used if there are visible signs of deterioration. This component may transmit infection Must be administered using a suitable transfusion set incorporating a 170 – 200 µm filter.



Confirmed Group

CMV Antibody Negative

Expiry 09 May 2025 21:27



939999999399917796

C- E- c+ e+ K- Jka- HbS-Neg



54270



Expiry 09/05/2025



O Neg

APPENDIX I

E Progesa Codabar Component Code: 54271

E Progesa ISBT – 128 Component Code: E8213V00

Product Name
WHOLE BLOOD, Reconstituted, Suitable for
Neonatal Use, Irradiated
HCT:.....

Shelf life 6 hours

Labelling and Barcode:

(for illustration purposes only - barcodes not suitable for scanning - label not to scale)



IBTS ver 4.0

WHOLE BLOOD, Reconstituted, Suitable for Neonatal Use, Irradiated.

HCT:

Store at $4^{\circ}C \pm 2^{\circ}C$



Drawn 09 May 2025



E8213V00

This component must not be used if there are visible signs of deterioration. This component may transmit infection Must be administered using a suitable transfusion set incorporating a 170 - 200 µm filter.



Rh D Negative

CMV Antibody Negative IRRADIATED (24 H) Confirmed Group

300



0251202120

Expiry 09 May 2025 21:28



C- E- c+ e+ S- K- HbS-Neg



54271



Expiry 09/05/2025



A Neg